Personalized medicine faster in days *
Using Micar21 technology (Genetic screen SNP (mutation) analysis and drug resistance) are the cornerstone for the successful future development of faster personalized medicine
Historically, healthcare has been built on developing and prescribing a universal principle. In this model, it may take tens of thousands of potential drug compounds introducing a process that can cost billions of dollars and take up to fifteen years to complete to cause potentially only one drug to make it to market.
The majority of these costs and time due to wear. Learning the hard way that the drug compounds are not effective, have unacceptable side effects, or only work for a fraction of the population. To work with this model from an economic point of view, and considering additional pressures for short periods of patent protection resulting from drug to be a blockbuster, generating billions of dollars in revenue through prescriptions of the largest possible number of patients.
Unfortunately, patients are the same. Many diseases are complex genetics that may be present in a similar way, but may have different performance requirements and therefore different treatments.